Preoperative D-dimer and outcomes in obstructive hypertrophic cardiomyopathy after myectomy

Tao Lu1, Changsheng Zhu1, Hao Cui2

  • 1Department of Adult Cardiac Surgery, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

PubMed

Insights

Elevated D-dimer levels predict increased mortality risk in patients undergoing septal myectomy for hypertrophic cardiomyopathy. This finding offers a valuable prognostic marker for improved patient management and outcomes.

Area of Science:

  • Cardiology
  • Biomarkers
  • Surgical Outcomes

Background:

  • The prognostic value of D-dimer in hypertrophic cardiomyopathy (HCM) patients undergoing septal myectomy is not well-established.
  • Septal myectomy is a key intervention for symptomatic HCM, but predicting long-term outcomes remains crucial.

Purpose of the Study:

  • To investigate the association between D-dimer levels and mortality in patients who underwent septal myectomy.
  • To determine if D-dimer can serve as a prognostic biomarker for all-cause and cardiovascular mortality.

Main Methods:

  • Retrospective analysis of 728 patients undergoing septal myectomy (2009-2018).
  • D-dimer levels categorized into tertiles; Cox regression and competing risk models used.
  • Primary endpoint: all-cause mortality; Secondary endpoint: cardiovascular mortality.

Main Results:

  • Higher D-dimer levels correlated with older age, female sex, and more severe mitral regurgitation.
  • An optimal cutoff of 0.29 mg/L for D-dimer predicted 5-year mortality.
  • D-dimer >0.29 mg/L significantly increased risk for all-cause (HR 3.12) and cardiovascular mortality (HR 3.29), independent of other factors.
  • Inclusion of D-dimer improved mortality prediction models.

Conclusions:

  • D-dimer is a significant predictor of mid-to-long-term all-cause and cardiovascular mortality in patients after septal myectomy.
  • D-dimer offers a robust, accessible biomarker for risk stratification in this patient population.
  • These findings support the integration of D-dimer testing into the prognostic assessment of HCM patients undergoing surgery.
Abstract

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...